Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Drug Use Investigation for Larotrectinib

NCT04945330 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04945330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04945330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Drug Use Investigation for Larotrectinib
Lead sponsor
Bayer
Phase
Observational
Overall status
Recruiting
Start date
November 5, 2021
Completion date
December 31, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or recurrent solid tumor harboring an ntrk gene fusion